With less than a week until the European Commission's final ruling, the 'internet-famous sweetener' erythritol is facing anti-dumping and countervailing investigations from the USA (referred to as 'double investigation'). In the latest announcement, Sanyuan Biotechnology stated that the double investigation against China's erythritol is still in the investigation stage, and the impact on the company's production and operation is uncertain. On the afternoon of December 17, the reporter repeatedly called Sanyuan Biotechnology's investor communication hotline but was informed that the call could not be connected. Amid the continuous double investigations in Europe and the USA, the price of erythritol has rebounded compared to the previous 'price war' period since the second half of 2023. That afternoon, the reporter called the office of the secretaries of the board of directors of two other erythritol manufacturers, Baolingbao Biology (002286.SZ, stock price 7.98 yuan, Market Cap 2.951 billion yuan) and Huakang Co., Ltd. (605077.SH, stock price 15.16 yuan, Market Cap 4.637 billion yuan). The former stated that the USA is one of its main markets, but specific interview matters need to be responded to by the company's senior management; the latter stated that the company's current sales volume is not large. The reporter also sent an interview outline to the listed companies via email. As of the time of publication, Baolingbao Biology and Sanyuan Biotechnology have not further responded. (Everyday)